By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central Florida, Pensacola, FL 2. Mayo Clinic, Rochester, MN 3. University of Washington/Fred Hutch Cancer Center, Seattle, WA
The International Innovation Grant will Fund Research on the Effectiveness of Community Screening Programs for the Early Detection of Oral Cancers in Nepal. The Binaytara Foundation and the Binaytara Foundation Cancer
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates
More
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This
More
By Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is
More
By Dr. Kanak Parmar Texas Tech University Perioperative systemic therapy for resectable non-small cell lung cancer Surgical resection followed by adjuvant chemotherapy has been the standard of care for the last
More
By Dr. Tarik Hadid Wayne State University Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that
More
By Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a
More
By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a
More
By Dr. Harsh Parmar Hackensack Meridian Health In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,
More
Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
More